Today, Relmada announced that its pharmacokinetic (PK) study in 30 healthy volunteers for BuTab, its orally ingestible formulation of buprenorphine, was successful and achieved safe and effective blood levels of the drug. As a reminder, currently none of the marketed forms of buprenorphine (which have >$1bn annual sales in the US combined) can be swallowed as they are sublingual, buccal or patch formulations.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.